Show simple item record

Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

dc.contributor.authorMerseburger, Axel Stuart
dc.contributor.authorChi, Kim N.
dc.contributor.authorChowdhury, Simon
dc.contributor.authorBjartell, Anders
dc.contributor.authorChung, Byung Ha
dc.contributor.authorde Santana Gomes, Andrea Juliana Pereira
dc.contributor.authorGiven, Robert
dc.contributor.authorSoto, Alvaro Juarez
dc.contributor.authorÖZGÜROĞLU, Mustafa
dc.contributor.authorUemura, Hirotsugu
dc.contributor.authorYe Dingwei, Ye Dingwei
dc.contributor.authorTriantos, Spyros
dc.contributor.authorMundle, Suneel
dc.contributor.authorMcCarthy, Sharon Anne
dc.contributor.authorLarsen, Julie S.
dc.contributor.authorSun Weili, Sun Weili
dc.contributor.authorBevans, Katherine
dc.contributor.authorZhang Ke, Zhang Ke
dc.contributor.authorBandyopadhyay, Nibedita
dc.contributor.authorAgarwal, Neeraj
dc.date.accessioned2021-12-10T09:39:47Z
dc.date.available2021-12-10T09:39:47Z
dc.date.issued2021
dc.identifier.citationChi K. N. , Chowdhury S., Bjartell A., Chung B. H. , de Santana Gomes A. J. P. , Given R., Soto A. J. , Merseburger A. S. , ÖZGÜROĞLU M., Uemura H., et al., "Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).", JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.6, 2021
dc.identifier.issn0732-183X
dc.identifier.otherav_0ab8c804-54bf-4dce-904a-54e66d6442bd
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/168206
dc.identifier.urihttps://doi.org/10.1200/jco.2021.39.6_suppl.11
dc.language.isoeng
dc.subjectDahili Tıp Bilimleri
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectOncology
dc.subjectHealth Sciences
dc.titleFinal analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).
dc.typeMakale
dc.relation.journalJOURNAL OF CLINICAL ONCOLOGY
dc.contributor.departmentBC Canc , ,
dc.identifier.volume39
dc.identifier.issue6
dc.contributor.firstauthorID2615883


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record